The research report by CITIC Construction Investment points out that AI is driving the pharmaceutical industry to undergo a transformation in its underlying logic and accelerating its commercialization process. The traditional pharmaceutical industry is constrained by the dilemmas of high investment, long cycles, and low success rates. However, AI technology has penetrated key areas such as target identification, virtual screening, novel drug design, ADMET prediction, and automated synthesis, breaking through the limitations of traditional high-throughput physical screening and significantly enhancing pharmaceutical efficiency and success rates. Currently, the AI-driven pharmaceutical industry chain has formed a network structure centered around platforms and technology middleware, with close collaboration between upstream and downstream sectors, and is demonstrating a trend of parallel development of multiple business models. It is predicted that the global AI pharmaceutical market will reach approximately $2.49 billion by 2025 and is expected to exceed $46 billion by 2035, with a compound annual growth rate exceeding 33%. The growth rate in the Chinese market is consistent with the global trend, and it is poised to become one of the most potential incremental markets.